‘This opens the door to the courts’ second-guessing any FDA approval — especially for drugs for controversial areas like gender-affirming care,’ expert says.
‘This opens the door to the courts’ second-guessing any FDA approval — especially for drugs for controversial areas like gender-affirming care,’ expert says.